NCT04547998已完成不适用
A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 24
- 主要终点
- Incidence of ≥80% Study Area Repigmentation
研究概览
简要总结
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
The Central Review Committee (CRC) will be blinded to treatment assignment when adjudicating data.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Focal, segmental or generalized (i.e., nonsegmental) stable vitiligo, defined as no new depigmented areas nor any depigmented areas that have expanded in size within the preceding 12 months, regardless of whether the areas are intended to be used as study areas.
- •1a. Photo documentation (current and at least 12 months prior) of the patient's depigmented areas have been evaluated as stable by an independent Screening Committee.
- •The patient has not undergone topical treatment (e.g., steroids, tacrolimus) for the study areas within the past 90 days.
- •The patient has not undergone phototherapy (e.g., NB-UVB) for the study areas within the past 90 days.
- •The patient is a candidate for surgical intervention of a depigmented area, defined as a patient who has previously been compliant with but has not satisfactorily responded to both
- •a. topical therapy and b. a minimum of 3 months of phototherapy.
- •The patient must have two study areas available for treatment that:
- •are of similar size (±50%),
- •are between 16cm2 and 456cm2 (contiguous),
- •are similarly sun exposed,
- •have the same extent of leukotrichia, and
- •are judged clinically as ≥90% depigmented (by area).
- •The patient is 18 years of age or older.
- •The patient is willing and able to comply with post-treatment at-home phototherapy and all follow-up evaluations required by the study protocol.
- •The patient agrees to abstain from any other treatment of the study areas for the duration of his/her participation in the study (52 weeks).
- •The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation in the study (52 weeks).
- •In the opinion of the investigator, the patient must be able to:
- •a. Understand the full nature and purpose of the study, including possible risks and adverse events, b. Understand instructions, and c. Provide voluntary written informed consent.
排除标准
- •The study areas selected have concomitant dermatologic conditions other than vitiligo.
- •The study area selected for treatment includes the lips, eyelids, plantar surface of feet, palmar surface of hands, fingertips, wrists, ankles, elbows, or knees.
- •The patient is unable to undergo the treatment area preparation.
- •Patients who are pregnant.
- •Patients with:
- •universalis vitiligo,
- •depigmented areas over >30% of their body surface area,
- •depigmented lips and fingertips (lip-tip vitiligo), or
- •> 3 depigmented fingertips, defined as depigmentation of the dorsal aspect of the fingertip from the distal interphalangeal joint to the tip of the digit.
- •Patients with recent history (within previous 12 months) of:
- •Koebnerization,
- •confetti-like, or
- •trichrome lesions.
- •Patients with a history of keloid formation.
- •Patients who have used a tanning salon in the past 60 days.
- •The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.
- •Current use of medications (e.g., anticoagulants such as heparin or warfarin) that in the investigator's opinion may compromise patient safety or trial objectives.
- •The patient has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution.
- •Life expectancy is less than 1 year.
结局指标
主要结局
Incidence of ≥80% Study Area Repigmentation
时间窗: Week 24
Repigmentation was evaluated by qualified members of a Central Review Committee.
次要结局
- Repigmentation Category(Week 24)
- Color Matching(Week 24)
研究者
研究点 (24)
Loading locations...
相似试验
终止
不适用
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo LesionsVitiligoNCT04271501Avita Medical5
已完成
4 期
Preemptive and Preventive Use of Paracetamol for Pain Relief After Cesarean SectionCesarean Section DehiscenceNCT02714179Baskent University54
已完成
不适用
Prospective randomized observer-blinded study comparing the analgesic efficacy of ultrasound-guided rectus sheath block to local anesthetic infiltration for laparoscopic percutaneous extraperitoneal closurelaparoscopic inguinal hernia surgery of children performed under general anesthesiaJPRN-UMIN000020912Hokkaido University34
已完成
不适用
Reducing radiation exposure during InterStim lead placementOveractive bladder, fecal incontinenceNervous System DiseasesISRCTN37385347Metro Health Hospital40
已完成
不适用
Local Wound Infiltration With 0.5% Levobupivacaine for Postoperative Pain After Laparoscopic Colorectal Surgery.Laparoscopic Colorectal SurgeryColorectal CancerNCT03433014Mahidol University30